Recombinant Human BACE1/ASP2 Protein (Active)

ASP2, BACE, HSPC104

Measured by its ability to cleave a fluorescent peptide substrate Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Lys(Dpn)-Arg-Arg-NH2 (Catalog# ES004; R&D Systems). Cleavage of ES004 can be measured using excitation and emission wavelength of 320 and 405 nm; respectively. The specific activity is >3.5 pmoles/min/ug.

Met 1-Thr 457

This product is provided as lyophilized powder which is shipped with ice packs.

< 1.0 EU per ug as determined by the LAL method.

49 kDa

Lyophilized from sterile 50mM Tris; 100mM NaCl; pH 8.0

Beta-site APP-cleaving enzyme 1 (BACE1) is an aspartic-acid protease important in the formation of myelin sheaths in peripheral nerve cells. In the brain; This protein is expressed highly in the substantia nigra; locus coruleus and medulla oblongata. Strong BACE1 expression has also been described in pancreatic tissue. BACE1 has a pivotal role in the pathogenesis of Alzheimer's disease. In Alzheimer's disease patients; BACE1 levels were elevated although mRNA levels were not changed. It has been found that BACE1 gene expression is controlled by a TATA-less promoter. The translational repression as a new mechanism controlling its expression. And the low concentrations of Ca(2+) (microM range) significantly increased the proteolytic activity of BACE1. Furthermore; BACE1 protein is ubiquitinated; and the degradation of BACE1 proteins and amyloid precursor protein processing are regulated by the ubiquitin-proteasome pathway. It has also been identified as the rate limiting enzyme for amyloid-beta-peptide (Abeta) production.